Metis TechBio Co., Ltd. (HKG:7666)

Market Cap	21.73B
Revenue (ttm)	298.03M +17,319.0%
Net Income	-408.16M
EPS	-0.46
Shares Out	1.18B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,861,222
Open	18.30
Previous Close	18.37
Day's Range	16.87 - 19.15
52-Week Range	9.46 - 29.98
Beta	n/a
Analysts	Strong Buy
Price Target	24.64 (+44.94%)
Earnings Date	Aug 25, 2026

About Metis TechBio

Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. It develops NanoForge, a suite of synergistic technologies that includes novo lipid library, AI foundational models, METiSAIAgent, quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. The company also develops specialized platforms, such as AiTEM, AiLNP and AiRNA that simulate, predict, and interpret nan...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 150
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 7666

Financial Performance

In 2025, Metis TechBio's revenue was 105.00 million, an increase of 6985.02% compared to the previous year's 1.48 million. Losses were -391.84 million, -21.51% less than in 2024.

Financial numbers in CNY

Analyst Summary

According to 3 analysts, the average rating for 7666 stock is "Strong Buy." The 12-month stock price target is $24.64, which is an increase of 44.94% from the latest price.

Price Target

$24.64

(44.94% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error